Tilogotamab Biosimilar – Anti-TNFRSF10B mAb – Research Grade from ProteoGenix; catalogue PX-TA1725; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tilogotamab Biosimilar – Anti-TNFRSF10B mAb – Research Grade: A Promising Antibody for Targeting TNFRSF10B
Tilogotamab Biosimilar is a monoclonal antibody (mAb) that specifically targets TNFRSF10B, also known as Death Receptor 5 (DR5). This biosimilar is a highly effective therapeutic agent that has shown promising results in preclinical studies and is currently being evaluated in clinical trials. In this article, we will explore the structure, activity, and potential applications of Tilogotamab Biosimilar as an anti-TNFRSF10B mAb.
Tilogotamab Biosimilar is a fully human IgG1 mAb that is produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to TNFRSF10B, while the constant region determines the effector functions of the antibody.
TNFRSF10B is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed on the surface of various cancer cells and plays a crucial role in promoting tumor cell survival and proliferation. Tilogotamab Biosimilar binds to TNFRSF10B with high affinity and blocks its interaction with its ligand, TRAIL (TNF-related apoptosis-inducing ligand). This prevents the activation of downstream signaling pathways that promote tumor growth and survival, ultimately leading to tumor cell death.
Targeting TNFRSF10B in
Tilogotamab Biosimilar has shown promising results in preclinical studies as a potential anti- cancer therapy. It has been demonstrated to be effective against a wide range of tumor types, including breast, lung, colon, and pancreatic cancer. In addition, it has been shown to have synergistic effects when combined with other anti- cancer agents, making it a promising candidate for combination therapy.
Tilogotamab Biosimilar is also a valuable tool for studying TNFRSF10B in research settings. Its high specificity and affinity for TNFRSF10B make it a suitable antibody for detecting and quantifying the expression of this receptor in various cancer cell lines and tissues. It can also be used to investigate the role of TNFRSF10B in cancer progression and to identify potential therapeutic targets for drug development.
Tilogotamab Biosimilar is currently being evaluated in clinical trials for the treatment of various solid tumors, including breast, lung, and ovarian cancer. The results from these trials have shown promising efficacy and safety profiles, and the biosimilar has been well-tolerated by patients. If successful, Tilogotamab Biosimilar has the potential to become a new treatment option for cancer patients.
Tilogotamab Biosimilar is a promising anti-TNFRSF10B mAb that has shown potential as a therapeutic agent in preclinical studies and is currently being evaluated in clinical trials. Its unique mechanism of action and high specificity make it a valuable tool for targeting TNFRSF10B in cancer therapy and research. With further development and clinical validation, Tilogotamab Biosimilar has the potential to become a valuable addition to the arsenal of anti- cancer agents.
ProteoGenix catalogue number PX-TA1725. For research use only.
Target: Tilogotamab Biosimilar – Anti-TNFRSF10B mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tilogotamab Biosimilar – Anti-TNFRSF10B mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
